“The company expects to have an interesting flow of news with a lot of potential triggers in the short and long term. During the current year and down the line a number of important milestones are expected to be reached, which – if development goes to plan – should indicate a positive development curve.”

Analyst: Jonas Söderström.
Read more here.

“During the autumn the company has made progress with its drug candidate ROSgard™ in terms of demonstrating safety and safeguarding large-scale manufacture. This, in combination with positive (if preliminary) indications of efficacy in kidney protection in connection with cancer treatment, means that we are seeing greater value in the project portfolio compared with before.”

Analyst: Markus Augustsson och Niklas Elmhammer, Jarl Securities.
Read more here.

“We have been positively surprised by the collaboration with CSL Behring. There is undeniably a great deal of asset-creating potential, as prospective combination treatments with recombinant A1M protein and plasma proteins may increase the number of indications.”
Read more here.

Small Cap
“The company’s orphan drug designation is definitely a strong plus, as is the fact that A1M is a biological medicinal product.”

Analyst: Niklas Elmhammer.
Read more here.
A1M Pharma AB | Scheelevägen 22 | 223 63 Lund
+46 46 286 50 30 |
Legal disclaimer | © Copyright - A1M